This result suggests that, given the complexity and the variety of the TGF-β superfamily of ligands, receptors, and binding proteins, TGF-β1 gene polymorphisms alone may not sufficiently explain the reduced susceptibility and severity of atherosclerosis observed among studied CKD patients. The gene discussed is TGFB1; the disease is chronic kidney disease.